WallStreetZenWallStreetZen

NASDAQ: ALZN
Alzamend Neuro Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ALZN

Based on 1 analyst offering 12 month price targets for Alzamend Neuro Inc

Min Forecast
$28.00+2,176.42%
Avg Forecast
$28.00+2,176.42%
Max Forecast
$28.00+2,176.42%

Should I buy or sell ALZN stock?

Based on 1 analyst offering ratings for Alzamend Neuro Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ALZN stock forecasts and price targets.

ALZN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-22

1 of 1

Forecast return on equity

Is ALZN forecast to generate an efficient return?

Company
-152.78%
Industry
96.68%
Market
175.93%
ALZN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ALZN forecast to generate an efficient return on assets?

Company
-82.57%
Industry
28.07%
ALZN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ALZN earnings per share forecast

What is ALZN's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$2.63
Avg 2 year Forecast
-$2.65
Avg 3 year Forecast
-$3.10

ALZN revenue forecast

What is ALZN's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

ALZN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ALZN$1.23$28.00+2,176.42%Buy
FBLG$0.89$74.00+8,186.67%Strong Buy
BGMS$0.84N/AN/A
CLGN$0.33N/AN/A
MTNB$0.75N/AN/A
View Top Biotech Stocks

Alzamend Neuro Stock Forecast FAQ

Is Alzamend Neuro Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ALZN) stock is to Buy ALZN stock.

Out of 1 analyst, 0 (0%) are recommending ALZN as a Strong Buy, 1 (100%) are recommending ALZN as a Buy, 0 (0%) are recommending ALZN as a Hold, 0 (0%) are recommending ALZN as a Sell, and 0 (0%) are recommending ALZN as a Strong Sell.

If you're new to stock investing, here's how to buy Alzamend Neuro stock.

What is ALZN's earnings growth forecast for 2026-2028?

(NASDAQ: ALZN) Alzamend Neuro's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.71%.

Alzamend Neuro's earnings in 2026 is -$7,632,109.On average, 3 Wall Street analysts forecast ALZN's earnings for 2026 to be -$10,012,556, with the lowest ALZN earnings forecast at -$9,619,907, and the highest ALZN earnings forecast at -$10,307,043. On average, 3 Wall Street analysts forecast ALZN's earnings for 2027 to be -$10,090,173, with the lowest ALZN earnings forecast at -$9,694,480, and the highest ALZN earnings forecast at -$10,386,943.

In 2028, ALZN is forecast to generate -$11,797,741 in earnings, with the lowest earnings forecast at -$11,335,084 and the highest earnings forecast at -$12,144,733.

What is ALZN's revenue growth forecast for 2026-2028?

(NASDAQ: ALZN) Alzamend Neuro's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.98%.

Alzamend Neuro's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast ALZN's revenue for 2026 to be $0, with the lowest ALZN revenue forecast at $0, and the highest ALZN revenue forecast at $0. On average, 3 Wall Street analysts forecast ALZN's revenue for 2027 to be $0, with the lowest ALZN revenue forecast at $0, and the highest ALZN revenue forecast at $0.

In 2028, ALZN is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is ALZN's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ALZN) forecast ROA is -82.57%, which is lower than the forecast US Biotechnology industry average of 28.07%.

What is ALZN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ALZN price target, the average ALZN price target is $28.00, with the highest ALZN stock price forecast at $28.00 and the lowest ALZN stock price forecast at $28.00.

The Wall Street analyst predicted that Alzamend Neuro's share price could reach $28.00 by Dec 22, 2026. The average Alzamend Neuro stock price prediction forecasts a potential upside of 2,176.42% from the current ALZN share price of $1.23.

What is ALZN's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ALZN) Alzamend Neuro's current Earnings Per Share (EPS) is -$4.18. On average, analysts forecast that ALZN's EPS will be -$2.63 for 2026, with the lowest EPS forecast at -$2.53, and the highest EPS forecast at -$2.71. On average, analysts forecast that ALZN's EPS will be -$2.65 for 2027, with the lowest EPS forecast at -$2.55, and the highest EPS forecast at -$2.73. In 2028, ALZN's EPS is forecast to hit -$3.10 (min: -$2.98, max: -$3.19).

What is ALZN's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ALZN) forecast ROE is -152.78%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.